Ozempic has become one of the most talked-about medications in modern medicine — and for good reason. Originally approved to manage blood sugar in adults with type 2 diabetes, Ozempic has earned a second reputation as a powerful weight-loss tool. Celebrities, physicians, and millions of everyday patients have turned to this once-weekly injectable as a solution for stubborn weight that lifestyle changes alone couldn't budge.

But does it actually work? And is it right for you? In this guide, we'll break down exactly what Ozempic is, how it drives weight loss, what the clinical data shows, who qualifies, and what your options are — including affordable compounded semaglutide alternatives available through telehealth providers like Truventa Medical.

What Is Ozempic?

Ozempic is a brand-name prescription medication containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It was developed by Novo Nordisk and received FDA approval in 2017 for the treatment of type 2 diabetes in adults. The drug is administered as a once-weekly subcutaneous (under the skin) injection, typically in the abdomen, thigh, or upper arm.

Semaglutide mimics a naturally occurring hormone called GLP-1, which plays a central role in blood sugar regulation. The medication comes in a pre-filled pen and is available in doses of 0.5 mg, 1 mg, and 2 mg — with patients typically starting at a low dose and titrating upward over several months.

It's important to note: Ozempic is not FDA-approved specifically for weight loss. However, its chemical cousin Wegovy — a higher-dose version of semaglutide (2.4 mg) — was approved in 2021 specifically for chronic weight management. Many physicians prescribe Ozempic "off-label" for weight loss, a common and legal medical practice.

How Ozempic Works for Weight Loss

GLP-1 receptor agonists like semaglutide drive weight loss through several complementary mechanisms that go well beyond simple appetite suppression:

  • Appetite regulation: Semaglutide acts on GLP-1 receptors in the brain — particularly in the hypothalamus — to reduce hunger signals and increase feelings of fullness. Patients consistently report eating significantly less without feeling deprived.
  • Slowed gastric emptying: Ozempic slows the rate at which food leaves your stomach, prolonging satiety after meals and reducing post-meal blood sugar spikes.
  • Reduced food cravings: Research suggests semaglutide may also dampen the reward signals associated with highly palatable foods, making it easier to resist overeating.
  • Improved insulin sensitivity: By optimizing insulin secretion in response to meals and reducing glucagon (a hormone that raises blood sugar), Ozempic creates a more favorable metabolic environment — one that supports fat loss rather than fat storage.

Together, these effects produce a sustained caloric deficit that can drive meaningful weight loss over months of treatment.

What Do the Clinical Trials Show?

The evidence for semaglutide's weight-loss effects is robust. The landmark STEP trial program — a series of large randomized controlled trials — studied semaglutide 2.4 mg (Wegovy) in people with obesity or overweight:

  • STEP 1: Adults with obesity (no diabetes) lost an average of 14.9% of body weight over 68 weeks — more than three times the weight loss seen with placebo.
  • STEP 3: When combined with intensive behavioral therapy, average weight loss reached 16%.
  • STEP 4: Participants who continued semaglutide maintained their weight loss, while those who switched to placebo regained most of the weight — underscoring the chronic nature of obesity treatment.

For context, lifestyle interventions alone typically produce 3–5% weight loss, and older weight-loss medications rarely exceeded 5–7%. Semaglutide's results represent a genuine leap forward in obesity pharmacotherapy.

Studies using Ozempic's 0.5 mg and 1 mg doses (approved for diabetes) also show meaningful weight loss — typically 5–10% of body weight — making off-label Ozempic a viable option for many patients who don't qualify for or can't access Wegovy.

Who Qualifies for Ozempic or Semaglutide?

Access to semaglutide — whether as Ozempic, Wegovy, or compounded versions — depends on your medical history and clinical criteria. Broadly, candidates include:

  • Adults with a BMI ≥ 30 (obesity)
  • Adults with a BMI ≥ 27 plus at least one weight-related health condition (hypertension, type 2 diabetes, high cholesterol, obstructive sleep apnea)
  • Adults with type 2 diabetes who need improved glycemic control alongside weight management

Semaglutide is not appropriate for everyone. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should also be used with caution in patients with a history of pancreatitis or severe gastrointestinal disease.

At Truventa Medical, our licensed providers conduct a thorough medical intake to confirm you're a good candidate before prescribing any GLP-1 medication.

Off-Label Ozempic vs. Wegovy: What's the Difference?

If you've done your research, you may wonder why your provider might prescribe Ozempic rather than Wegovy for weight loss. The distinction is largely about dose and FDA indication:

  • Ozempic (semaglutide 0.5–2 mg): FDA-approved for type 2 diabetes. Prescribed off-label for weight loss. Same active ingredient as Wegovy.
  • Wegovy (semaglutide 2.4 mg): FDA-approved specifically for chronic weight management. The higher dose generally produces greater weight loss in clinical trials.

Off-label prescribing is entirely legal and extremely common in medicine. Your provider may choose Ozempic if you have diabetes, if Wegovy is unavailable due to supply shortages, or for other clinical reasons.

Compounded Semaglutide: A More Accessible Alternative

Brand-name Ozempic and Wegovy carry list prices of $900–$1,400 per month without insurance — a significant barrier for many patients. Compounded semaglutide offers a clinically equivalent alternative at a fraction of the cost.

FDA-registered compounding pharmacies can legally produce semaglutide injections that contain the same active molecule. While not FDA-approved as a finished drug product, compounded medications are a well-established part of American healthcare and are prescribed routinely when brand-name drugs are unavailable or unaffordable.

Through Truventa Medical's weight loss program, patients can access physician-prescribed compounded semaglutide for as little as $199–$299 per month — including provider consultations, dosing guidance, and ongoing clinical support. This approach puts effective GLP-1 therapy within reach for patients who couldn't otherwise afford brand-name options.

Side Effects of Ozempic

Like all medications, semaglutide carries potential side effects. The most commonly reported are gastrointestinal and tend to be most pronounced early in treatment or after dose increases:

  • Nausea (most common — affects up to 44% of users, usually mild to moderate)
  • Vomiting
  • Diarrhea or constipation
  • Stomach discomfort or bloating
  • Decreased appetite (often a desired effect)

These side effects typically diminish as the body adjusts to the medication. Slow dose titration — starting at the lowest dose and increasing gradually — is the most effective strategy to minimize GI discomfort.

Less common but more serious risks include pancreatitis, gallbladder disease, and kidney problems (often secondary to dehydration from vomiting/diarrhea). The FDA has also noted a potential risk of thyroid C-cell tumors based on animal studies, though this has not been confirmed in humans.

Your Truventa Medical provider will review your complete health history to assess your individual risk profile before prescribing.

How Much Does Ozempic Cost?

Cost is one of the biggest factors patients consider when evaluating semaglutide therapy:

  • Brand-name Ozempic: ~$936/month without insurance. With manufacturer savings cards (for commercially insured patients), costs may drop to $25/month for eligible patients.
  • Brand-name Wegovy: ~$1,350/month without insurance. Similar savings programs exist.
  • Compounded semaglutide via telehealth: $199–$350/month, depending on dose and provider — no insurance required.

Insurance coverage for Ozempic used off-label for weight loss is inconsistent — many plans cover it for diabetes but not for weight management. Wegovy coverage is expanding but remains limited. For most patients without employer-sponsored coverage that includes GLP-1s, compounded semaglutide through a telehealth program like Truventa Medical is the most practical and affordable path.